

Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims:

1. - 24. (Canceled)

25. **(Currently Amended)** An isolated recombinant polypeptide comprising:
(a) the amino acid sequence SEQ ID NO:2[[:] or,
(b) ~~an immunogenic fragment of 15 or more contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject coupled to a suitable carrier or in a composition, which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.~~

26. (Canceled)

27. **(Canceled)**

28. (Canceled)

29. **(Currently Amended)** ~~The isolated recombinant polypeptide of claim 25, wherein the polypeptide comprises~~ An isolated recombinant polypeptide comprising an immunogenic fragment of 15 or more contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include coupled to a suitable carrier coupled to the polypeptide or in a composition which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

30. (Canceled)

31. **(Currently Amended)** The isolated recombinant polypeptide of claim 25 29, wherein the immunogenic fragment ~~of (b)~~ comprises 20 or more contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include coupled to a suitable carrier coupled to the polypeptide or in a composition which can include an adjuvant, is capable of inducing an antibody that specifically binds to said fragment within SEQ ID NO:2.

32. (Previously Presented) The isolated recombinant polypeptide of claim 25, wherein the isolated recombinant polypeptide consists of SEQ ID NO:2.

33-34. (Canceled)

35. (**Currently Amended**) A fusion protein comprising the isolated recombinant polypeptide of claim 25.

36. - 39. (Canceled)

40. (**Currently Amended**) An immunogenic composition comprising the isolated recombinant polypeptide of claim 25 and a pharmaceutically acceptable carrier.

41. (Previously Presented) The immunogenic composition of claim 40, wherein the immunogenic composition further comprises at least one other *Neisseria meningitidis* antigen other than a polypeptide comprising SEQ ID NO:2.

42. (Canceled)

43. (Previously Presented) A method for inducing an antibody in a mammal comprising administering the isolated recombinant polypeptide of claim 25 to the mammal in an amount effective to induce an antibody.

44. - 47. (Canceled)

48. (**Canceled**)

49. (**Canceled**)

50. (**Currently Amended**) A fusion protein comprising the isolated recombinant polypeptide of claim 29.

51. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 29 and a pharmaceutically acceptable carrier.

52. - 56. (Canceled)

57. (**Currently Amended**) A fusion protein comprising the isolated recombinant polypeptide of claim 31.

58. (Canceled)

59. (Previously Presented) An immunogenic composition comprising the isolated recombinant polypeptide of claim 31 and a pharmaceutically acceptable carrier.

60. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 35 and a pharmaceutically acceptable carrier.

61. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 48 and a pharmaceutically acceptable carrier.

62. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 50 and a pharmaceutically acceptable carrier.

63. (Previously Presented) An immunogenic composition comprising the fusion protein of claim 57 and a pharmaceutically acceptable carrier.

64. (New) The immunogenic composition of claim 40, further comprising an adjuvant.

65. (New) The immunogenic composition of claim 51, further comprising an adjuvant.

66. (New) The immunogenic composition of claim 59, further comprising an adjuvant.

67. (New) The immunogenic composition of claim 60, further comprising an adjuvant.

68. (New) The immunogenic composition of claim 61, further comprising an adjuvant.

69. (New) The immunogenic composition of claim 62, further comprising an adjuvant.

70. (New) The immunogenic composition of claim 63, further comprising an adjuvant.

71. (New) The isolated recombinant polypeptide of claim 29, wherein the polypeptide is coupled to a carrier.

72. (New) The isolated recombinant polypeptide of claim 31, wherein the polypeptide is coupled to a carrier.